12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PledOx calmangafodipir: Phase IIb ongoing

PledPharma dosed the first patient in the randomized portion of the double-blind, placebo-controlled, international Phase IIb PLIANT trial evaluating 2 and 10 µmol/kg IV PledOx given 30 minutes prior to FOLFOX6 (5-FU, leucovorin, and oxaliplatin) chemotherapy. The randomized portion is enrolling 126 mCRC patients....

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >